This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Two novel events drove the 2020 data: the inclusion of Early Access content in the JCR for the first time, and the sudden appearance of COVID-19 as an entirely new, extremely urgent field of study. These factors made the 2020 data explored in last year’s release particularly unusual.
However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. He received an MD from the Georg August University of Göttingen and completed a postdoctoral Master’s in MedicalSciences Clinical Pharmacology at the University of Glasgow.
Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. Andreas held several senior executive roles, including Senior Vice President of MedicalSciences at ImClone Systems, Inc., later acquired by Eli Lilly and Company.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content